Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

scientific article published on 01 October 2019

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) is …
instance of (P31):
scholarly articleQ13442814
case reportQ2782326

External links are
P356DOI10.3390/CELLS8101186
P932PMC publication ID6829309
P698PubMed publication ID31581548

P50authorGiuseppe ToffoliQ54252459
Elena De MattiaQ57023125
Rossana RoncatoQ57207645
Marica GarzieraQ61145262
Erika CecchinQ63887282
Vincenzo CanzonieriQ72677293
Fabrizio EccaQ90460651
P2093author name stringElena Poletto
Simona Scalone
Giorgio Giorda
Roberto Sorio
Loredana Romanato
Sara Gagno
P2860cites workIdentification of a novel p53 functional domain that is necessary for efficient growth suppressionQ24311276
Mutation and cancer: statistical study of retinoblastomaQ24618185
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancerQ27824864
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upQ27851444
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.Q27851687
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerQ27851709
Integrated genomic analyses of ovarian carcinomaQ27860518
Cancer statistics, 2015Q27860576
Structural basis for the binding of proline-rich peptides to SH3 domainsQ29620408
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.Q31109634
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapyQ33186850
WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical studyQ33239524
Integrated analysis of germline and somatic variants in ovarian cancer.Q33630954
Clonal evolution of chemotherapy-resistant urothelial carcinoma.Q41315076
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.Q41721778
TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functionsQ42324763
Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skinQ42548348
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damageQ43256441
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cellsQ43854589
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutationsQ44023983
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerQ44461877
Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.Q46004659
p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancerQ46769388
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Q47111129
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survivalQ47773300
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Q48227450
Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.Q48602026
Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental studyQ49337608
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.Q49960798
Whole-genome characterization of chemoresistant ovarian cancerQ50272478
Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancerQ33679037
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genesQ34044691
p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.Q34060903
Integrative eQTL-based analyses reveal the biology of breast cancer risk lociQ34194768
Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapyQ34389383
A simple p53 functional assay for screening cell lines, blood, and tumorsQ34397902
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Q34775855
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemiaQ35407650
DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a reviewQ35562351
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patientsQ35906322
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic LeukemiaQ35984259
Patterns and functional implications of rare germline variants across 12 cancer typesQ36437964
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomasQ36493279
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencingQ36910793
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyQ36912591
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancerQ37046405
Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancerQ37257019
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profilingQ37395388
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian CarcinomasQ37595954
Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemQ37611723
Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancerQ37762683
Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the driversQ38087850
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.Q38170493
Alternative splicing in cancer: implications for biology and therapyQ38179828
Ki67 is a promising molecular target in the diagnosis of cancer (review).Q38266652
The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and ExpandedQ38787667
Somatic TP53 Mutations in the Era of Genome Sequencing.Q38922539
Next-Generation Sequencing: Role in Gynecologic CancersQ38944589
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.Q38966664
Navigating the challenge of tumor heterogeneity in cancer therapyQ39255308
Tumor Evolution as a Therapeutic TargetQ39448954
Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis.Q39761795
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7.Q40084373
Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinomaQ40154485
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patientsQ40622483
The codon 72 polymorphic variants of p53 have markedly different apoptotic potentialQ40672888
Complex analysis of the p53 tumor suppressor in lung carcinoma.Q51560589
Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.Q52663623
Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.Q52900611
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Q53054061
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).Q55259197
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsQ57797237
LOH rather than genotypes ofTP53codon 72 is associated with disease-free survival in primary breast cancerQ58213042
Somatic mutation profiling of vulvar cancer: Exploring therapeutic targetsQ59357513
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing DataQ60146452
Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent diseaseQ60683143
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancerQ64054918
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic StandpointsQ64111448
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methodsQ77522152
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomasQ79435490
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysisQ80019806
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ86063198
The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancerQ87399723
Treatment resistance in urothelial carcinoma: an evolutionary perspectiveQ88548676
Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor TissueQ89218812
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) ApproachQ92733309
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue10
P921main subjectovarian cancerQ172341
P577publication date2019-10-01
P1433published inCellsQ27724621
P1476titleClonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
P478volume8

Search more.